Holen Sie sich die Stockscreener-App
8.99
4.29%
0.37
Schlusskurs vom Vortag:
$8.62
Offen:
$8.65
24-Stunden-Volumen:
156.23K
Relative Volume:
0.46
Marktkapitalisierung:
$297.40M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-7.0787
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
+5.02%
1M Leistung:
-3.85%
6M Leistung:
-34.71%
1J Leistung:
+28.25%
1-Tages-Spanne:
$8.65
$9.17
1-Wochen-Bereich:
$8.17
$9.17
52-Wochen-Spanne:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
8.99 | 278.55M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
Neuropace (NPCE) Stock: A Bearish Crossroads of Technical and Fundamental Risks - AInvest
FY2029 EPS Estimates for NeuroPace Raised by Leerink Partnrs - MarketBeat
Leerink Partnrs Expects Increased Earnings for NeuroPace - MarketBeat
What is HC Wainwright's Forecast for NeuroPace Q1 Earnings? - MarketBeat
Lord Abbett & CO. LLC Takes Position in NeuroPace, Inc. $NPCE - MarketBeat
Wells Fargo & Company Lowers NeuroPace (NASDAQ:NPCE) Price Target to $15.00 - MarketBeat
Equities Analysts Set Expectations for NeuroPace Q3 Earnings - MarketBeat
Deutsche Bank AG Has $11.36 Million Holdings in NeuroPace, Inc. $NPCE - MarketBeat
Moving Average Crossover Confirms Uptrend in NeuroPace Inc.July 2025 Weekly Recap & AI Enhanced Execution Alerts - newsyoung.net
AI Trend Models Suggest Bounce for NeuroPace Inc.July 2025 Weekly Recap & High Accuracy Buy Signal Tips - newsimpact.co.kr
NeuroPace Inc. stock daily chart insightsPortfolio Gains Report & Weekly Market Pulse Alerts - Newser
Q3 Earnings Estimate for NeuroPace Issued By HC Wainwright - Defense World
NeuroPace (NASDAQ:NPCE) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
How hedge fund analytics apply to NeuroPace Inc. stockMarket Activity Summary & Low Risk High Win Rate Stock Picks - Newser
Will NeuroPace Inc. bounce back from current supportJuly 2025 EndofMonth & Capital Protection Trading Alerts - Newser
Regression analysis insights on NeuroPace Inc. performanceWeekly Gains Summary & Stepwise Trade Signal Implementation - Newser
Is NeuroPace Inc. stock ready for a breakoutTrade Risk Assessment & Low Volatility Stock Recommendations - Newser
Price momentum metrics for NeuroPace Inc. explainedMarket Movement Recap & Expert Approved Momentum Ideas - Newser
NeuroPace FY2025 EPS Estimate Boosted by Cantor Fitzgerald - MarketBeat
What risks could impact NeuroPace Inc. stock performance2025 Top Gainers & Daily Price Action Insights - Newser
Why NeuroPace Inc. stock attracts strong analyst attentionPortfolio Performance Summary & Fast Moving Stock Trade Plans - Newser
Cantor Fitzgerald Boosts Earnings Estimates for NeuroPace - Defense World
What is HC Wainwright’s Forecast for NeuroPace Q1 Earnings? - Defense World
FY2025 EPS Estimates for NeuroPace Lifted by Leerink Partnrs - Defense World
Neuropace’s Innovative Approach to Treating Lennox-Gastaut Syndrome - MSN
Reversal indicators forming on NeuroPace Inc. stockJuly 2025 Breakouts & Safe Capital Growth Tips - Newser
Is NeuroPace Inc. in a long term uptrend2025 AllTime Highs & High Accuracy Swing Entry Alerts - thegnnews.com
NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
NeuroPace stock price target lowered to $13 by Wolfe Research - Investing.com South Africa
Wells Fargo Reaffirms Buy Rating on NeuroPace with $15 Price Target - AInvest
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $15 - 富途牛牛
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
NeuroPace, Inc. (NASDAQ:NPCE) Q2 2025 Earnings Call Transcript - Insider Monkey
NeuroPace Q2 Loss Wider Than Expected, Revenue Exceeds ForecastsNews and Statistics - IndexBox
NeuroPace 2025 Q2 Earnings Revenue Growth Amid Sustained Net Loss - AInvest
NeuroPace stock price target lowered to $15 by Wells Fargo on wider loss forecast - Investing.com South Africa
NeuroPace Inc.: Q2 Earnings Snapshot - Connecticut Post
NeuroPace Expects FDA Submission for Expanded IGE Indication in 2H 2025 - AInvest
NeuroPace Q2 Revenue Hits $23.5M, Up 22% YoY, With Gross Margin at 77.1% - AInvest
NeuroPace Inc (NPCE) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... By GuruFocus - Investing.com Canada
NeuroPace Reports Record Revenue and Raises Guidance - TipRanks
Is NeuroPace Inc. in Accumulation Phase NowAI Based High Gain Watchlist Scanner Shared - beatles.ru
NeuroPace Q2 2025 Earnings Call Transcript - MarketBeat
NeuroPace raises 2025 revenue guidance to $94M-$98M as RNS System drives record growth - MSN
NeuroPace: Building a Durable Moat in Epilepsy Treatment with AI-Driven Innovation and Expanding Indications - AInvest
NeuroPace Revenue Jumps 22 Percent in Q2 - Nasdaq
NeuroPace Raises 2025 Revenue Guidance to $94M-$98M, Driven by RNS System Growth - AInvest
NeuroPace's Q2 2025 Earnings Call: Unraveling Key Contradictions in Growth, Margins, and Strategy - AInvest
NeuroPace, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NPCE) - Seeking Alpha
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neuropace Inc-Aktie (NPCE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):